NeuroPace (NPCE) Expected to Announce Earnings on Wednesday

NeuroPace (NASDAQ:NPCE) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect NeuroPace to post earnings of ($0.26) per share and revenue of $21.85 million for the quarter.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. The firm had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.14 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Trading Up 2.7%

Shares of NPCE opened at $12.89 on Monday. The firm’s 50-day moving average price is $11.53 and its 200-day moving average price is $11.32. The firm has a market capitalization of $422.19 million, a price-to-earnings ratio of -12.89 and a beta of 2.04. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. NeuroPace has a 1-year low of $5.45 and a 1-year high of $15.11.

Insider Buying and Selling

In other news, insider Martha Morrell sold 78,334 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total value of $1,074,742.48. Following the transaction, the insider now owns 81,993 shares in the company, valued at approximately $1,124,943.96. This represents a 48.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. 22.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

NPCE has been the topic of a number of research reports. UBS Group initiated coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price on the stock. Cantor Fitzgerald boosted their price objective on shares of NeuroPace from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, Wells Fargo & Company boosted their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.20.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.